| | A Perfect 10 for 2020
The Koch Institute is ringing in the New Year with a 10/10—again! For more than a year, the Koch Institute community has been working on the renewal process for our Cancer Center Support Grant from the National Cancer Institute. Since MIT’s then-nascent Center for Cancer Research was distinguished as an NCI-designated Cancer Center in 1974, the grant has been recompeted every five years, requiring an extensive written application (more than 1,000 pages!) and an intense site visit. Given the vulnerability of federal research funding, there are no guarantees of success. Yet not only has the Koch Institute’s grant been formally approved for renewal, but it was given a perfect score of 10. We received the same score at our last recompete, in 2014. Join us in raising a glass to our faculty members, trainees, technicians, and staff who worked so hard to put the grant together and to defend it during the site visit! |
|
Homing in on Hypoxia
Inspired by a desire to work on pressing, unaddressed medical needs, Cima Lab postdoc Greg Ekchian is developing a way to measure oxygen levels in tumors in order to improve cancer treatment. Until now, clinicians have been unable to quickly assess tumor tissue for areas of hypoxia (oxygen deprivation). Hypoxic areas can drive chemoresistance, but respond to high-dose radiation. Working with clinical collaborators through the Bridge Project, Ekchian is testing the strategy in a pilot trial of cervical cancer patients. In another project supported by the Koch Institute Frontier Research Program, he is developing a more advanced version of the original device. |
|
|
Hojun Li Joins the KI
Welcome to Hojun Li, MD, PhD, the KI’s new Charles W. and Jennifer C. Johnson Clinical Investigator. A pediatric oncologist at Dana-Farber/Boston Children’s Hospital, he recently received a 2020 Scholar Award from the American Society of Hematology.
Dr. Li studies normal and pathologic hematopoietic stem cell development, conditions that predispose children and adults to leukemia, and novel treatments to prevent blood cancers in these patients. |
|
|
Amon Fights Back Against Dysfunction
Angelika Amon, the Kathleen and Curtis Marble Professor in Cancer Research, is taking aim at both cell dysfunction and imprecise language in her investigations of aging, cancer, and Down syndrome. Spectrum explores how Amon’s research is driven by the pursuit of clear, simple “grandma-friendly” questions that link basic biology to human health. |
|
|
Treg-ulating Immunosuppression in Cancer
New research from the Jacks and Regev Labs—led by former graduate student Amy Li, whose work was partly supported by a Margaret A. Cunningham Immune Mechanisms in Cancer Research Fellowship—uncovers how immune cells called Tregs can promote immunosuppression in cancer. Using single-cell RNA sequencing to longitudinally profile changes in Tregs in a mouse model of lung cancer, the study points to the role of a specific immune cell receptor and highlights potential paths for therapeutic intervention. |
|
|
Mind Your PNAS QnAs
PNAS queries Sangeeta Bhatia, director of the Marble Center for Cancer Nanomedicine, on her work building protease-based diagnostic tools, including probes—potentially delivered by a nebulizer—that distinguish between benign and malignant lung nodules. Other highlights include diagnostic tools for pneumonia and a rare genetic disease called α-1 antitrypsin deficiency.
|
|
|
Science Nonfiction Double Feature
Two Langer Lab devices aim to improve global health. A monthly capsule could provide a more reliable and discreet form of contraceptive, particularly for women in developing countries. A quantum dot dye stores vaccination history under the skin’s surface to help improve vaccination rates in areas where medical records are often missing or nonexistent. |
|
|
Cancer, à la Carte
The Tech puts the spotlight on the Vander Heiden Lab, where researchers are seeking to starve out cancer cells. Cancer cells adapt normal metabolic processes to support proliferation, becoming dependent on specific nutrients. By identifying which nutrients are on the menu, the team hopes to target specific, treatment-resistant cancer cells for starvation. |
|
|
Better Foundations for Breast Cancer Diagnostics
Foundation Medicine, co-founded by KI member Eric Lander, reports two advances in breast cancer diagnostics. The FDA approved the FoundationOne CDx test to select patients for treatment of HR+/HER2- breast cancer with PIK3CA mutations. In a clinical study, the company’s FoundationOne liquid biopsy test accurately predicted the risk of recurrence for early-stage triple-negative breast cancer. |
|
|
|
|
